Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial

The Lancet Respiratory Medicine

Volumn 2, Issue 6, 2014, Pages 455-463

  Mandal, Pallavi ^a   Chalmers, James D ^b   Graham, Catriona ^c   Harley, Catherine ^d   Sidhu, Manjit K ^a   Doherty, Catherine ^e   Govan, John W ^e   Sethi, Tariq ^f   Davidson, Donald J ^a   Rossi, Adriano G ^a   Hill, Adam T ^a,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e Zoonotic and Animal Pathogens Research Laboratory   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BRONCHIECTASIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG MEGADOSE; DRUG WITHDRAWAL; HEADACHE; HEMATURIA; HUMAN; LEG PAIN; LEICESTER COUGH QUESTIONNAIRE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPUTUM; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; ADOLESCENT; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BRONCHIECTASIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901855503     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70050-5     Document Type: Article

References (42)

1. Mandal P, Hill AT Bronchiectasis: breaking the cycle of inflammation and infection. Lancet Respir Med 2013, 1:e5-e6.
2. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002, 57:15-19.
3. Cole PJ A new look at the pathogenesis, management of persistent bronchial sepsis: a 'vicious circle' hypothesis and its logical therapeutic connotations. Strategies for the management of chronic bacterial sepsis 1984, 1-20. Medicine Publishing Foundation, Oxford. R.J. Davies (Ed.).
4. Wilson CB, Jones PW, O'Leary CJ, et al. Systemic markers of inflammation in stable bronchiectasis. Eur Respir J 1998, 12:820-824.
5. Dinarello CA Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
6. Kwak B, Mulhaupt F, Myit S, Mach F Statins as a newly recognized type of immunomodulator. Nat Med 2000, 6:1399-1402.
7. Shyamsundar M, McKeown ST, O'Kane CM, et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114.
8. Fessler MB, Young SK, Jeyaseelan S, et al. A role for HMG coenzyme A reductase in pulmonary inflammation and host defense. Am J Respir Crit Care Med 2005, 171:606-615.
9. Chow OA, von Kockritz-Blickwede M, Bright AT, et al. Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 2010, 8:445-454.
10. McDowell SA, Ma Y, Kusano R, Akinbi HT Simvastatin is protective during Staphylococcus aureus pneumonia. Curr Pharm Biotechnol 2011, 12:1455-1462.
11. Boyd AR, Hinojosa CA, Rodriguez PJ, Orihuela CJ Impact of oral simvastatin therapy on acute lung injury in mice during pneumococcal pneumonia. BMC Microbiol 2012, 12:73.
12. Chalmers JD, Singanayagam A, Murray MP, Hill AT Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008, 121:1002-1007.
13. Davies G, Well AU, Doffman S, Watanabe S, Wilson R The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006, 28:974-979.
14. Martinez-Garcia MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565-1572.
15. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003, 58:339-343.
16. Murray MP, Turnbull K, MacQuarrie S, Pentland JL, Hill AT Validation of the Leicester Cough Questionnaire in non cystic fibrosis bronchiectasis. Eur Respir J 2009, 34:125-131.
17. Singh SJ, Morgan MDL, Scott SC, et al. The development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992, 47:1019-1024.
18. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R Validation of the St George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997, 156:536-541.
19. Mikami M, Llewellyn-Jones CG, Bayley D, Hill SL, Stockley RA The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998, 157:723-728.
20. Spanevello G, Migliori GB, Sharara A, et al. Induced sputum to assess airway inflammation: a study of reproducibility. Clin Exp Allergy 1997, 27:1138-1144.
21. Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004, 59:231-236.
22. Hill AT, Bayley D, Stockley RA The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999, 160:893-898.
23. Stockley RA, Bayley DL Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000, 15:778-781.
24. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000, 109:288-295.
25. Pasteur MC, Bilton D, Hill AT British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010, 65(suppl 1):1-58.
26. Wang MT, Lo YW, Tsai CL, et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am J Med 2013, 126:598-606.
27. Lahousse L, Loth DW, Joos GF, et al. Statins, systemic inflammation and risk of death in COPD: the Rotterdam study. Pulm Pharmacol Ther 2013, 26:212-217.
28. Li Y, Gottlieb J, Ma D, et al. Graft-protective effects of the HMG-CoA reductase inhibitor pravastatin after lung transplantation: a propensity score analysis with 23 years of follow-up. Transplantation 2011, 92:486-492.
29. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections. a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667.
30. Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006, 12:1056-1064.
31. Leitch AE, Lucas CD, Marwick JA, Duffin R, Haslett C, Rossi AG Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation. Cell Death Differ 2012, 19:1950-1961.
32. Koedel U, Klein M, Pfister HW Modulation of brain injury as a target of adjunctive therapy in bacterial meningitis. Curr Infect Dis Rep 2010, 12:266-273.
33. Wood WG, Igbavboa U, Muller WE, Eckert GP Statins, Bcl-2, and apoptosis: cell death or cell protection?. Mol Neurobiol 2013, 48:308-314.
34. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005, 112:117-124.
35. Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease. J Immunol 2006, 176:7657-7665.
36. Houck JC Chemical messengers of the inflammatory process 1979, Elsevier/North-Holland Biomedical Press, Oxford.
37. Llewellyn-Jones CG, Johnson MM, Mitchell JL, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995, 8:1479-1487.
38. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
39. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013, 309:1260-1267.
40. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 2013, 309:1251-1259.
41. Valery PC, Morris PS, Byrnes CA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med 2013, 1:610-620.
42. British National Formulary number 67: chapter 2, cardiovascular system-section 2.12, lipid-lowering drugs; statins 2014, Joint Formulary Committee, BMJ Publishing Group and Royal Pharmaceutical Society, London.